[go: up one dir, main page]

IL162836A0 - Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments - Google Patents

Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments

Info

Publication number
IL162836A0
IL162836A0 IL16283603A IL16283603A IL162836A0 IL 162836 A0 IL162836 A0 IL 162836A0 IL 16283603 A IL16283603 A IL 16283603A IL 16283603 A IL16283603 A IL 16283603A IL 162836 A0 IL162836 A0 IL 162836A0
Authority
IL
Israel
Prior art keywords
nucleic acid
peptides
peptidommetics
treatments
acid damaging
Prior art date
Application number
IL16283603A
Other languages
English (en)
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of IL162836A0 publication Critical patent/IL162836A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16283603A 2002-01-17 2003-01-17 Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments IL162836A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35020802P 2002-01-17 2002-01-17
PCT/IB2003/000425 WO2003059942A2 (en) 2002-01-17 2003-01-17 Peptides and peptidomimetics having anti-proliferative activity and their use

Publications (1)

Publication Number Publication Date
IL162836A0 true IL162836A0 (en) 2005-11-20

Family

ID=23375680

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16283603A IL162836A0 (en) 2002-01-17 2003-01-17 Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
IL162836A IL162836A (en) 2002-01-17 2004-07-01 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162836A IL162836A (en) 2002-01-17 2004-07-01 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof

Country Status (18)

Country Link
US (3) US6995135B2 (xx)
EP (1) EP1483290B1 (xx)
JP (3) JP4041066B2 (xx)
KR (2) KR100863090B1 (xx)
CN (2) CN101092455B (xx)
AT (1) ATE404584T1 (xx)
AU (2) AU2003235576C1 (xx)
CA (1) CA2471192C (xx)
CY (1) CY1108470T1 (xx)
DE (1) DE60322845D1 (xx)
DK (1) DK1483290T3 (xx)
ES (1) ES2311703T3 (xx)
IL (2) IL162836A0 (xx)
NO (1) NO332461B1 (xx)
PT (1) PT1483290E (xx)
SI (1) SI1483290T1 (xx)
WO (1) WO2003059942A2 (xx)
ZA (1) ZA200405455B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4041066B2 (ja) * 2002-01-17 2008-01-30 武田薬品工業株式会社 抗増殖活性を有し、そして／または核酸損傷剤を増大するペプチドおよびペプチド模倣物あるいは処置
ES2369534T3 (es) * 2002-06-06 2011-12-01 Canbas Co. Ltd. Compuestos que anulan el punto de control g2 del ciclo celular inducido por daños en el adn y/o que incrementan la actividad anticancerosa de los tratamientos que dañan el adn.
US20100210745A1 (en) * 2002-09-09 2010-08-19 Reactive Surfaces, Ltd. Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes
US20100233146A1 (en) * 2002-09-09 2010-09-16 Reactive Surfaces, Ltd. Coatings and Surface Treatments Having Active Enzymes and Peptides
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20090238811A1 (en) * 2002-09-09 2009-09-24 Mcdaniel C Steven Enzymatic Antimicrobial and Antifouling Coatings and Polymeric Materials
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
JP4705567B2 (ja) * 2003-06-25 2011-06-22 株式会社 キャンバス 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物
US8618066B1 (en) 2003-07-03 2013-12-31 Reactive Surfaces, Ltd., Llp Coating compositions having peptidic antimicrobial additives and antimicrobial additives of other configurations
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
US20060286006A1 (en) * 2005-06-21 2006-12-21 Mcdaniel C S Method and apparatus for the treatment of fluid waste streams
CA2666184A1 (en) * 2006-10-11 2008-04-17 Medvet Science Pty. Ltd. The use of a dna damaging agent and a ligand for the treatment of cancer
US8629650B2 (en) * 2008-05-13 2014-01-14 Qualcomm Incorporated Wireless power transfer using multiple transmit antennas
TW201000116A (en) * 2008-05-14 2010-01-01 Takeda Pharmaceutical Peptide compound and use thereof
US8388904B1 (en) 2008-12-22 2013-03-05 Reactive Surfaces, Ltd., Llp Equipment decontamination system and method
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
SG179021A1 (en) * 2009-09-15 2012-04-27 Reactive Surface Ltd Anti-fouling paints and coatings
WO2013033645A1 (en) * 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
RU2732440C2 (ru) * 2013-06-24 2020-09-16 Кэнбас Ко., Лтд. Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
HRP20191254T1 (hr) * 2014-05-21 2019-10-18 Entrada Therapeutics, Inc. Peptidi koji prodiru u stanice i postupci za njihovu proizvodnju i uporabu
EP3185880B1 (en) 2014-08-27 2020-02-12 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
CN114989254B (zh) * 2022-06-17 2023-11-03 中山大学 一种多肽及其设计方法和在制备抑制具核梭杆菌产品或预防结直肠癌药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385257A1 (en) * 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
WO2001094411A1 (en) * 2000-06-05 2001-12-13 The Regents Of The University Of California Peptides modulating protease activated receptors and methods of using same
JP4041066B2 (ja) * 2002-01-17 2008-01-30 武田薬品工業株式会社 抗増殖活性を有し、そして／または核酸損傷剤を増大するペプチドおよびペプチド模倣物あるいは処置

Also Published As

Publication number Publication date
KR20040081750A (ko) 2004-09-22
KR101103412B1 (ko) 2012-01-06
CN100360564C (zh) 2008-01-09
US7476657B2 (en) 2009-01-13
EP1483290A2 (en) 2004-12-08
EP1483290B1 (en) 2008-08-13
HK1069179A1 (en) 2005-05-13
NO20043381L (no) 2004-10-12
US20060084610A1 (en) 2006-04-20
JP4873646B2 (ja) 2012-02-08
CY1108470T1 (el) 2014-04-09
JP2008044946A (ja) 2008-02-28
IL162836A (en) 2011-09-27
DK1483290T3 (da) 2008-11-03
AU2003235576A1 (en) 2003-07-30
KR100863090B1 (ko) 2008-10-13
WO2003059942A3 (en) 2004-10-07
DE60322845D1 (de) 2008-09-25
NO332461B1 (no) 2012-09-24
CA2471192C (en) 2014-05-20
WO2003059942A9 (en) 2003-11-27
ES2311703T3 (es) 2009-02-16
ATE404584T1 (de) 2008-08-15
AU2003235576C1 (en) 2009-12-10
JP2005529845A (ja) 2005-10-06
KR20080006649A (ko) 2008-01-16
AU2009201711A1 (en) 2009-05-21
JP4041066B2 (ja) 2008-01-30
CA2471192A1 (en) 2003-07-24
AU2003235576B2 (en) 2009-01-29
US20090253635A1 (en) 2009-10-08
AU2009201711B2 (en) 2011-12-15
JP2011037896A (ja) 2011-02-24
US6995135B2 (en) 2006-02-07
CN1642978A (zh) 2005-07-20
SI1483290T1 (sl) 2009-02-28
US20040248783A1 (en) 2004-12-09
ZA200405455B (en) 2005-08-31
PT1483290E (pt) 2008-09-19
CN101092455B (zh) 2012-07-04
CN101092455A (zh) 2007-12-26
WO2003059942A2 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
IL162836A0 (en) Peptides and peptidommetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
TW200502385A (en) Modulation of forkhead box o1a expression
GB0223038D0 (en) Therapeutic compounds
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
NZ517616A (en) Use of retigabin for treating neuropathic pain
PT1796660T (pt) Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
IL161591A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
MY137757A (en) Therapeutic treatment
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
AU6178198A (en) Method of treating a tumor
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
NO954880L (no) Cytidin deaminase
EP1407752A4 (en) COMPOSITE POWDERS AND SKIN PREPARATIONS FOR EXTERNAL USE CONTAINING THESE POWDERS
WO2002098362A3 (en) Use of rank antagonists to treat cancer
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
TW200738267A (en) Methods of increasing lymphatic function
SE0100684D0 (sv) New subject-matter
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
TW200508196A (en) Hydroxamic acids useful in the treatment of hyper-proliferative disorders
WO2005082353A3 (en) Use of beta-lapachone for treating or preventing cancer
PL377056A1 (pl) Nowe związki przeciwnowotworowe

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed